Concepedia

Author

Thomas Dejoie

Centre Hospitalier Universitaire de NantesORCID

Also Known As

Dejoie, Thomas, Pascale Jolliet, T Dejoie, T. Dejoie, THOMAS DEJOIE, Thomas Dejoie

108

Publications

3.4K

Citations

23

H-Index

67

Concepts

All Affiliations

Centre Hospitalier Universitaire de NantesNantes UniversitéInsermLaboratoire de Biologie Structurale de la CelluleInstitut universitaire du cancer de Toulouse Oncopole
TD

About

Thomas Dejoie is an author at Centre Hospitalier Universitaire de Nantes specializing in medicine, hematology, and immunology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

11

13

1.6K

2

Health Sciences

6

6

1.1K

3

Public Health

2

2

236

4

Social Sciences

2

2

34

5

Allied Health Professions

1

1

16

Thomas Dejoie

×

34

Publications

3K

Citations

21

H-Index

YearCitations

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

Philippe Moreau, Michel Attal, Cyrille Hulin,

The Lancet

2019

922

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

Aurore Perrot, Valérie Lauwers‐Cancès, Jill Corre,

Blood

2018

408

VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial

Philippe Moreau, Cyrille Hulin, Margaret Macro,

Blood

2016

273

Active smoking compromises IVF outcome and affects ovarian reserve

Thomas Fréour, Damien Masson, S. Mirallié,

Reproductive BioMedicine Online

2008

173

Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial

Philippe Moreau, Cyrille Hulin, Aurore Perrot,

The Lancet Oncology

2021

167

Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference

Christopher R. McCudden, Amy Axel, Dominique Slaets,

Clinical Chemistry and Laboratory Medicine (CCLM)

2016

116

Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial

Philippe Moreau, Cyrille Hulin, Aurore Perrot,

The Lancet Oncology

2024

94

Long‐term outcome of monoclonal (type 1) cryoglobulinemia

A. Néel, F. Perrin, Olivier Decaux,

American Journal of Hematology

2014

82

Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma

Thomas Dejoie, Jill Corre, Hélène Caillon,

Blood

2016

69

Effect of stress on clinical reasoning during simulated ambulatory consultations

P. Pottier, Thomas Dejoie, Jean-Benoît Hardouin,

Medical Teacher

2013

68

Page 1